Catalyst Calendar
Scope

Thu, Jun 25, 2026

1 updates
AVIR
7:00 AM

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026 More Than 880 HCV Treatment-Naïve Patients Enrolled Across 17 Countries Outside North America C-FORWARD and C-BEYOND Represent the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for the Treatment of HCV

Enrollment • Phase 3Enrollment completion Thu, Jun 25, 2026ateapharma.com

Wed, May 27, 2026

1 updates
AVIR
7:00 AM

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting Antiviral for the Treatment of Hepatitis E Virus BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc.

Presentation / Abstract • Phase 1EASL abstract release Thu, May 28, 2026, 8:30 AM CESTateapharma.com

Wed, May 13, 2026

1 updates
AVIR
7:00 AM

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been

Presentation / AbstractEASL abstract release Wed, May 13, 2026, 8:00 AM CETateapharma.com

Tue, May 12, 2026

1 updates

Tue, May 5, 2026

1 updates